B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS-Reference-Cited by-同舟云学术

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

Published:2022-02-24 Issue:5 Volume:31 Page:1103-1110
ISSN:1055-9965
Container-title:Cancer Epidemiology, Biomarkers & Prevention
language:en
Short-container-title:

Author:

Wang Sophia S.¹^ORCID,Vajdic Claire M.²^ORCID,Linet Martha S.³^ORCID,Slager Susan L.⁴^ORCID,Voutsinas Jenna¹,Nieters Alexandra⁵,Casabonne Delphine⁶⁷,Cerhan James R.⁴^ORCID,Cozen Wendy⁸^ORCID,Alarcón Graciela⁹,Martínez-Maza Otoniel¹⁰¹¹¹²^ORCID,Brown Elizabeth E.¹³¹⁴,Bracci Paige M.¹⁵,Turner Jennifer¹⁶¹⁷^ORCID,Hjalgrim Henrik¹⁸^ORCID,Bhatti Parveen¹⁹^ORCID,Zhang Yawei²⁰,Birmann Brenda M.²¹^ORCID,Flowers Christopher R.²²,Paltiel Ora²³,Holly Elizabeth A.¹⁵,Kane Eleanor²⁴^ORCID,Weisenburger Dennis D.²⁵^ORCID,Maynadié Marc²⁶^ORCID,Cocco Pierluigi²⁷^ORCID,Foretova Lenka²⁸,Breen Elizabeth Crabb²⁹^ORCID,Lan Qing³^ORCID,Brooks-Wilson Angela³⁰^ORCID,De Roos Anneclaire J.³¹,Smith Martyn T.³²,Roman Eve²⁴^ORCID,Boffetta Paolo³³³⁴^ORCID,Kricker Anne³⁵^ORCID,Zheng Tongzhang³⁶,Skibola Christine F.²²,Clavel Jacqueline³⁷^ORCID,Monnereau Alain³⁷³⁸,Chanock Stephen J.³,Rothman Nathaniel³,Benavente Yolanda⁶⁷,Hartge Patricia³,Smedby Karin E.³⁹

Affiliation:

1. 1Division of Health Analytics, Department of Computational and Quantitative Medicine, Beckman Research Institute of the City of Hope, Monrovia, California.

2. 2Centre for Big Data Research in Health, The University of New South Wales, Sydney, New South Wales, Australia.

3. 3Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.

4. 4Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.

5. 5The Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany.

6. 6Unit of Infections and Cancer, Epidemiology, Public Health, Cancer Prevention and Palliative Care Program – Epibell, IDIBELL, Institut Català d’ Oncologia/IDIBELL, Barcelona, Spain.

7. 7The Biomedical Research Centre Network for Epidemiology and Public Health (CIBERESP), Madrid, Spain.

8. 8Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, California.

9. 9Division of Clinical Immunology and Rheumatology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.

10. 10Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

11. 11Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

12. 12Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California.

13. 13Department of Pathology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.

14. 14O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, Alabama.

15. 15Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.

16. 16Department of Histopathology, Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia.

17. 17Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.

18. 18Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.

19. 19British Columbia Cancer Research Center, Vancouver, British Columbia, Canada.

20. 20Department of Cancer Prevention and Control at the National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

21. 21Channing Division of Network Medicine, Department of Medicine Research, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

22. 22Winship Cancer Institute, Emory University, Atlanta, Georgia.

23. 23Department of Hematology, The Hebrew University-Hadassah Braun School of Public Health and Community Medicine, Hadassah University Medical Center, Jerusalem, Israel.

24. 24Department of Health Sciences, University of York, York, United Kingdom.

25. 25Department of Pathology, City of Hope, Duarte, California.

26. 26Registry of Hematological Malignancies of Cote d'Or, INSERM U1231, Burgundy University and University Hospital, Dijon, France (Maynadie).

27. 27Occupational Health Section, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

28. 28Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic.

29. 29Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

30. 30Department of Biomedical Physiology and Kinesiology, Faculty of Science, Simon Fraser University, Vancouver, British Columbia, Canada.

31. 31Department of Environmental and Occupational Health, Dornsife School of Public Health, Drexel University, Philadelphia, Pennsylvania.

32. 32Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, Berkeley, California.

33. 33Stony Brook Cancer Center, Stony Brook University, Stony Brook, New York.

34. 34Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

35. 35Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia.

36. 36Department of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island.

37. 37Centre of Research in Epidemiology and Statistics (CRESS), UMR1153, INSERM, Université de Paris, Paris, France.

38. 38Registre des Hémopathies Malignes de la Gironde, Institut Bergonié, University of Bordeaux, Inserm, Team EPICENE, UMR 1219, Paris, France.

39. 39Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Abstract

Abstract Background: A previous International Lymphoma Epidemiology (InterLymph) Consortium evaluation of joint associations between five immune gene variants and autoimmune conditions reported interactions between B-cell response-mediated autoimmune conditions and the rs1800629 genotype on risk of B-cell non–Hodgkin lymphoma (NHL) subtypes. Here, we extend that evaluation using NHL subtype-specific polygenic risk scores (PRS) constructed from loci identified in genome-wide association studies of three common B-cell NHL subtypes. Methods: In a pooled analysis of NHL cases and controls of Caucasian descent from 14 participating InterLymph studies, we evaluated joint associations between B-cell–mediated autoimmune conditions and tertile (T) of PRS for risk of diffuse large B-cell lymphoma (DLBCL; n = 1,914), follicular lymphoma (n = 1,733), and marginal zone lymphoma (MZL; n = 407), using unconditional logistic regression. Results: We demonstrated a positive association of DLBCL PRS with DLBCL risk [T2 vs. T1: OR = 1.24; 95% confidence interval (CI), 1.08–1.43; T3 vs. T1: OR = 1.81; 95% CI, 1.59–2.07; P-trend (Ptrend) < 0.0001]. DLBCL risk also increased with increasing PRS tertile among those with an autoimmune condition, being highest for those with a B-cell–mediated autoimmune condition and a T3 PRS [OR = 6.46 vs. no autoimmune condition and a T1 PRS, Ptrend < 0.0001, P-interaction (Pinteraction) = 0.49]. Follicular lymphoma and MZL risk demonstrated no evidence of joint associations or significant Pinteraction. Conclusions: Our results suggest that PRS constructed from currently known subtype-specific loci may not necessarily capture biological pathways shared with autoimmune conditions. Impact: Targeted genetic (PRS) screening among population subsets with autoimmune conditions may offer opportunities for identifying those at highest risk for (and early detection from) DLBCL.

Funder

NIH

European Commission

European Regional Development Fund

AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA

Federal Office for Radiation Protection grants

José Carreras Leukemia Foundation

German Federal Ministry for Education and Research

Health Research Board, Ireland and Cancer Research Ireland MH CZ – DRO

MEYS – NPS I

NCI

NCI NIH Public Health Service